Clorox (NYSE:CLX) Upgraded to Hold at Zacks Research

Clorox (NYSE:CLX) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Rothschild & Co Redburn dropped their target price on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Morgan Stanley decreased their price target on shares of Clorox from $137.00 to $125.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Citigroup cut their price objective on shares of Clorox from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Clorox in a research report on Tuesday, October 14th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Clorox from $128.00 to $121.00 and set a “hold” rating on the stock in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Buy rating, thirteen have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $125.69.

Clorox Price Performance

Shares of CLX opened at $107.32 on Wednesday. The business has a 50-day moving average of $113.61 and a 200-day moving average of $121.36. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The company has a market capitalization of $13.09 billion, a price-to-earnings ratio of 16.46, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. Clorox has a 1 year low of $98.20 and a 1 year high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the previous year, the business earned $1.86 EPS. The firm’s revenue was down 18.9% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. As a group, equities research analysts anticipate that Clorox will post 7.15 earnings per share for the current year.

Insider Buying and Selling at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction on Friday, November 21st. The stock was purchased at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at $1,353,690. This represents a 44.44% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.63% of the stock is currently owned by company insiders.

Institutional Trading of Clorox

Institutional investors and hedge funds have recently modified their holdings of the business. Vermillion & White Wealth Management Group LLC purchased a new position in Clorox in the third quarter worth $25,000. CIBC Private Wealth Group LLC increased its position in Clorox by 3.7% in the third quarter. CIBC Private Wealth Group LLC now owns 8,969 shares of the company’s stock worth $1,106,000 after buying an additional 318 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Clorox in the third quarter valued at $5,576,000. Achmea Investment Management B.V. lifted its position in shares of Clorox by 3.1% during the 3rd quarter. Achmea Investment Management B.V. now owns 33,528 shares of the company’s stock valued at $4,134,000 after buying an additional 995 shares during the last quarter. Finally, WBI Investments LLC bought a new position in shares of Clorox during the 3rd quarter worth $541,000. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.